Home > DocuBase > Article

« All DocuBase Articles

 

Follow DocuTicker on Twitter   Feed

Wednesday, 12th January 2011

Medicare Payments for Newly Available Generic Drugs

Medicare Payments for Newly Available Generic Drugs (PDF)

Source:  U.S. Department of Health and Human Services, Office of Inspector General

Medicare and its beneficiaries could have saved an estimated $111 million had payment amounts reflected actual sales prices during the initial generic availability of 16 drugs.  These potential savings accounted for 25 percent of total expenditures for these drugs during the same period.

Manufacturers are required to submit average sales price (ASP) data to CMS within 30 days after the close of each quarter, and those data are used to calculate the payment amounts for the following quarter.  As a result, there is a two-quarter lag between when sales occur and when the payment amounts reflect those sales.  This reimbursement lag is especially problematic when newly available generic drugs enter the market, as their ASPs are often substantially lower than their brand counterparts, but payment amounts remain at the higher brand level for two quarters or more.

We found that payment amounts were significantly higher than market prices for an extended period for the newly available generic drugs under review.  In other words, during the period of initial generic availability, generic versions of these drugs were being administered or dispensed to beneficiaries, but Medicare was still paying brand prices.  Furthermore, according to the Food and Drug Administration, 26 of the 48 brand-only drugs with the highest Part B expenditures in 2008 could have first generic versions approved in the next several years, meaning that the vulnerability posed by the two-quarter lag likely will continue to grow.  Nearly half of the current high-dollar brand-only Part B drugs are biologics, which (because of recent legislation) may also gain approval in generic form.  Compounding the problem of the two-quarter lag are the significant obstacles that remain in identifying in advance when generic versions of drugs will become available.  Because of issues such as patent litigation and the generic manufacturers' timeliness in reporting ASPs, it is difficult to predict when first-generic versions will reach the market.

We recommend that CMS work with Congress to require manufacturers of first generics to submit monthly ASP data during the period of initial generic availability.  This could substantially reduce the two-quarter lag and make Medicare payment amounts more reflective of actual market prices.  If CMS finds this to be an effective means for alleviating the financial impact of the two-quarter lag, the agency may wish to consider requiring monthly ASP submissions for all Part B-covered drugs.

CMS did not concur with our recommendation, citing potential problems with manufacturer price submissions and increased administrative burdens under a proposed monthly ASP reporting requirement.  CMS also stated that it believes the two-quarter lag protects Medicare and its beneficiaries from unchecked price increases and is an incentive for faster generic utilization.  We believe that the savings from a reduced reimbursement lag may outweigh any issues involved with implementing a monthly ASP reporting system.  Furthermore, we note that the ASP-based reimbursement system (in which all versions of a drug assigned to one payment code are paid at the same amount) is a natural incentive for manufacturers to limit rapid price increases, as well as for providers to utilize generic versions.

 


Category:

Source:

Views: 1073




Please note: DocuTicker's editors collect citations for full-text PDF reports freely available on the web but we do not archive these reports. When you click a link to find and/or download the report, you are leaving the DocuTicker site. DocuTicker makes no representations regarding the ongoing availability of any report or any external resource. Links were accurate as of the date of posting.

« All DocuBase Articles

 

FreePint

FreePint supports the value of information in the enterprise. Read more »


FeedLatest FreePint Content:


  • Click to view the article Mini Review of NewsEdge Visualisation Features
    Friday, 27th February 2015

    Chris Porter takes a detailed look at the taxonomy-based visualisation components within news management tool NewsEdge.com. Highlights include its use of complex algorithm that helps determine relevancy and its striking Venn Diagram feature.

  • Click to view the article Tools that Take Us Beyond Search and Retrieval
    Friday, 27th February 2015

    Jan Sykes looks at recently published and upcoming articles and reviews in the Topic Series "Making Information Visible". She highlights content about tools and services which aim to facilitate discovery and ease of access to improve the user experience.

  • Click to view the article Product Review of AdisInsight (Trials - Value and Competitor Landscape)
    Friday, 27th February 2015

    In part 6 of his product review of Springer's new AdisInsight drug information platform, Ashish Shukla looks at the value of the coverage of key clinical trials, one of the three databases brought together under a single access point.

  • ... more ...

All FreePint Content »
FreePint Topics »


A FreePint Subscription delivers articles and reports that support your organisation's information practice, content and strategy.

Find out more and order a FreePint Subscription by visiting the
completing our online form: Subscription Order page.


FreePint Testimonials

"Thank you for coordinating this CoP. My colleague and I both found it quite valuable both in content and in hearing from others. We are looking ..."

Read more testimonials and supply yours »







 

 
 
 

Subscribe

Receive the DocuTicker Newsletter each week.

Find out more »

Article Categories

All Article Categories »

Sources

All DocuBase Sources »

Source Categories

All Source Categories »

Archive

All Archives »